发明名称 PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
摘要 The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.;
申请公布号 US2015291582(A1) 申请公布日期 2015.10.15
申请号 US201314434203 申请日期 2013.10.31
申请人 RAQUALIA PHARMA INC. 发明人 Kawamura Kiyoshi;Yamagishi Tatsuya;Arano Yoshimasa;Morita Mikio
分类号 C07D471/04;A61K31/5377;A61K31/437;A61K31/4545;A61K31/497;A61K31/4725;A61K31/444;A61K31/501 主分类号 C07D471/04
代理机构 代理人
主权项 1. A compound of the following formula (I): Wherein: A is aryl; B is selected from the group consisting of a chemical bond, —C1-6 alkylene-, —C1-6 alkylene-NR2—, —NR2—, and —(C═O)—; C is selected from the group consisting of a chemical bond, —(C═O)—, and —NR2—; R1 is independently selected from the group consisting of; (1) hydrogen, (2) —On—C1-6 alkyl where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, (3) —On—C3-7 cycloalkyl where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R11, (4) —On-aryl where the aryl is unsubstituted or substituted with one or more substituents independently selected from R11, (5) —S—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, (6) —S-aryl where the aryl is unsubstituted or substituted with one or more substituents independently selected from R11; (7) —NH—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, and (8) —NH-aryl, where the aryl is unsubstituted or substituted with one or more substituents independently selected from R11; wherein n is independently 0 or 1, when n is 0, a chemical bond is present in the place of —On—; R2 is independently selected from the group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (5) —On—C3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (6) —On—C2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents independently selected from R7, (7) —On-phenyl or —On-naphthyl, where the phenyl or naphthyl is unsubstituted or substituted with one or more substituents independently selected from R7, (8) —On-heterocyclyl, where the heterocyclyl is unsubstituted or substituted with one or more substituents independently selected from R7, (9) —(C═O)—NR8R9, (10) —NR8R9, (11) —S(O)2—NR8R9, (12) —NR8—S(O)2R9, (13) —S(O)t—R9, where t is 0, 1 or 2, (14) —NR8(C═O)R9, (15) —CN, and (16) —NO2; wherein n is independently 0 or 1, when n is 0, a chemical bond is present in the place of —On—; p is 1, 2, 3, or 4; when p is two or more than two, R2 may be same or different; R3 and R4 are independently hydrogen or C1-6 alkyl which is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, and —O—C1-6 alkyl; or R3 form a 3 to 7 membered ring with R4 which may contain nitrogen atom, oxygen atom, sulfur atom or double bond, wherein the 3 to 7 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen, (4) C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R11, (5) C3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents independently selected from R11, (6) —O—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, and (7) —O—C3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R11; R5 is independently selected from the group consisting of: (1) hydrogen, (2) halogen, (3) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (4) —On—C3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R7, and (5) —On—C2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents independently selected from R7; wherein n is independently 0 or 1, when n is 0, a chemical bond is present in the place of —On—; R5 may be anywhere on the pyrazolopyridine ring; q is 1, 2 or 3; when q is two or more than two, R5 may be same or different; R6 is independently hydrogen, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C3-7 cycloalkyl, —NR8R9, heterocyclyl, aryl, aryl-C1-6 alkyl, or heterocyclyl-C1-6 alkyl, where the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, the C3-7 cycloalkyl, the heterocyclyl, the aryl, the aryl-C1-6 alkyl, or the heterocyclyl-C1-6 alkyl, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, C1-6 alkyl, —O—C1-6 alkyl, —C3-7 cycloalkyl, —O—C3-7 cycloalkyl, hydroxyl-C1-6 alkoxy, —CN, —NR8R9, —(C═O)—R8, —(C═O)—NR8R9, —NR8—(C═O)—R9, —NR8—(C═O)—NR9R10, —NR8—(C═O)—OR9, —NR—S(O)2—R9, —NR8—S(O)2—NR9R10, and —S(O)2—R8; when B is —NR2— and C is —(C═O)—, R6 may form the 4-7 membered ring with R2; R7 is selected from the group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4) —(C═O)m—Ol—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, (5) —Ol—(C1-3)perfluoroalkyl, (6) —(C═O)m—Ol—C3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R11, (7) —(C═O)m—Ol—C2-4 alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents independently selected from R11, (8) —(C═O)m—Ol-phenyl or —(C═O)m—Ol-naphthyl, where the phenyl or naphthyl is unsubstituted or substituted with one or more substituents independently selected from R11, (9) —(C═O)m—Ol-heterocyclyl, where the heterocyclyl is unsubstituted or substituted with one or more substituents independently selected from R11, (10) —(C═O)—NR8R9, (11) —NR8R9, (12) —S(O)2—NR8R9, (13) —S(O)t—R8, where t is 0, 1 or 2, (14) —CO2H, (15) —CN, and (16) —NO2; wherein 1 is 0 or 1 and m is 0 or 1; when 1 is 0 or m is 0, a chemical bond is present in the place of —Ol— or —(C═O)m—, and when 1 is 0 and m is 0, a chemical bond is present in the place of —(C═O)m—Ol—; R8, R9, and R10 are independently hydrogen, C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl, or aryl, which is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, C1-6 alkyl, —O—C1-6 alkyl, C3-7 cycloalkyl, and —O—C3-7 cycloalkyl; or R8 form a 4 to 7 membered ring with R9 which may contain nitrogen atom, oxygen atom, sulfur atom or double bond, wherein the 4 to 7 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen, (4) C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R11, (5) C3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents independently selected from R11, (6) —O—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R11, and (7) —O—C3-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R11; R11 is independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen, (4) —C1-6 alkyl, which is unsubstituted or substituted with one or more halogen, (5) —C3-6 cycloalkyl, (6) —O—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more halogen, (7) —O(C═O)—C1-6 alkyl, (8) —NH—C1-6 alkyl, (9) phenyl, (10) heterocyclyl, (11) —CN, and (12) —Si(C1-6 alkyl)3; k is 1 or 2; r is 0 or 1, when r is 0, a chemical bond is present in the place of —[O]r—; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
地址 Aichi JP